Siramesine

Drug Profile

Siramesine

Alternative Names: LU-28179

Latest Information Update: 04 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Onxeo SA
  • Class Antidepressants; Anxiolytics; Indoles; Spiro compounds
  • Mechanism of Action Sigma-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Cancer; Major depressive disorder

Most Recent Events

  • 04 Sep 2014 Discontinued - Preclinical for Cancer in Denmark (PO)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 17 Sep 2008 Siramesine is still in preclinical trials for Cancer in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top